Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases

Author:

Fitzgerald Kathryn C12ORCID,Mecoli Christopher A3,Douglas Morgan1,Harris Samantha1,Aravidis Berna1,Albayda Jemima3,Sotirchos Elias S1,Hoke Ahmet1,Orbai Ana-Maria3,Petri Michelle3,Christopher-Stine Lisa3,Baer Alan N3,Paik Julie J3,Adler Brittany L3,Tiniakou Eleni3,Timlin Homa3,Bhargava Pavan1,Newsome Scott D1,Venkatesan Arun1,Chaudhry Vinay1,Lloyd Thomas E1,Pardo Carlos A1,Stern Barney J1,Lazarev Mark4,Truta Brindusa4,Saidha Shiv1,Chen Edward S5,Sharp Michelle5,Gilotra Nisha6,Kasper Edward K6,Gelber Allan C23,Bingham Clifton O3,Shah Ami A3,Mowry Ellen M12

Affiliation:

1. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

3. Division of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

4. Division of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

5. Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

6. Department of Cardiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Abstract

Abstract Background People with autoimmune or inflammatory conditions taking immunomodulatory/suppressive medications may have higher risk of novel coronavirus disease 2019 (COVID-19). Chronic disease care has also changed for many patients, with uncertain downstream consequences. Methods We included participants with autoimmune or inflammatory conditions followed by specialists at Johns Hopkins. Participants completed periodic surveys querying comorbidities, disease-modifying medications, exposures, COVID-19 testing and outcomes, social behaviors, and disruptions to healthcare. We assessed whether COVID-19 risk is higher among those on immunomodulating or suppressive agents and characterized pandemic-associated changes to care and mental health. Results In total, 265 (5.6%) developed COVID-19 over 9 months of follow-up (April–December 2020). Patient characteristics (age, race, comorbidity, medications) were associated with differences in social distancing behaviors during the pandemic. Glucocorticoid exposure was associated with higher odds of COVID-19 in models incorporating behavior and other potential confounders (odds ratio [OR]: 1.43; 95% confidence interval [CI]: 1.08, 1.89). Other medication classes were not associated with COVID-19 risk. Diabetes (OR: 1.72; 95% CI: 1.08, 2.73), cardiovascular disease (OR: 1.68; 95% CI: 1.24, 2.28), and kidney disease (OR: 1.76; 95% CI: 1.04, 2.97) were associated with higher odds of COVID-19. Of the 2156 reporting pre-pandemic utilization of infusion, mental health or rehabilitative services, 975 (45.2%) reported disruptions therein, which disproportionately affected individuals experiencing changes to employment or income. Conclusions Glucocorticoid exposure may increase risk of COVID-19 in people with autoimmune or inflammatory conditions. Disruption to healthcare and related services was common. Those with pandemic-related reduced income may be most vulnerable to care disruptions.

Funder

National MS Society

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Reference25 articles.

1. An Italian programme for COVID-19 infection in multiple sclerosis;Sormani;Lancet Neurol,2020

2. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response;Zabalza;Eur J Neurol

3. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study;Doran;Arthritis Rheum,2002

4. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study;Wijnands;J Neurol Neurosurg Psychiatry,2018

5. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies;Monti;Ann Rheum Dis,2020

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3